Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study

Hepato-Gastroenterology

Volumn 53, Issue 69, 2006, Pages 399-404

  Gisbert, Javier P ^a,d   Luna, Marta ^a   Maté, José ^a   González Guijarro, Luis ^b   Cara, Carlos ^c   Pajares, José María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c Celltech Pharma SA   (Spain)

^d NONE   (Spain)

Author keywords

6 mercaptopurine; Azathioprine; Crohn's disease; Inflammatory bowel disease; Leukopenia; Myelotoxicity; Thiopurine methyltransferase; TPMT; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CONTROLLED STUDY; CROHN DISEASE; DRUG HYPERSENSITIVITY; ENTERITIS; ERYTHROCYTE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG MONITORING; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; MALE; METHYLTRANSFERASES; PROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 33745460088     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000: CD000545.
2. Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000: CD000067.
3. Gisbert JP, Gomollon F, Mate J, Pajares JM: Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity. Rev Clin Esp 2002; 202:555-562.
4. Lennard L, Van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149-154.
5. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170:2-6; discussion 16-19.
6. Menor C, Fueyo JA, Escribano O, Cara C, Fernandez-Moreno MD, Roman ID, et al: Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit 2001; 23:536-541.
7. Snow JL, Gibson LE: The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131:193-197.
8. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:2293-2301.
9. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
10. Anstey A, Lennard L, Mayou SC, Kirby JD: Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85:752-756.
11. Lowry PW, Franklin CL, Weaver AL, Gennett Pike M, Mays DC, Tremaine WJ, et al: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49:665-670.
12. Lennard L: Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47:131-143.
13. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.
14. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM: Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 2003; 121:1-5.
15. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM: Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2:148-159.
16. Campbell S, Kingstone K, Ghosh S: Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16:389-398.
17. Menor C, Fueyo J, Escribano O, Pina MJ, Redondo P, Cara C, et al: Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients. Mult Scler 2002; 8:243-248.
18. Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H: Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 1995; 60:639-642.
19. Thervet E, Anglicheau D, Toledano N, Houllier AM, Noel LH, Kreis H, et al: Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol 2001; 12:170-176.
20. Weyer N, Kroplin T, Fricke L, Iven H: Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001; 57:129-136.
21. Chocair PR, Duley JA, Simmonds HA, Cameron JS: The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53:1051-1056.
22. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM: Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41:18-25.
23. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336:225-229.
24. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85:1897-902.
25. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M: Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995; 27:1298-1300.
26. Keuzenkamp-Jansen CW, Leegwater PA, De Abreu RA, Lambooy MA, Bokkerink JP, Trijbels JM: Thiopurine methyltransferase: a review and a clinical pilot study. J Chromatogr B Biomed Appl 1996; 678:15-22.
27. Szumlanski CL, Weinshilboum RM: Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39:456-459.
28. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, et al: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62:464-475.
29. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, et al: Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49:656-664.
30. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ: Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116:1505-1506.
31. Campbell S, Ghosh S: Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001; 13:1297-301.
32. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122:904-915.
33. Lennard L: Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20:527-531.
34. Lorenzen I, Brun C, Videbaek A: Treatment of immunologic diseases with cytostatics. Acta Med Scand 1969; 185:501-506.
35. Ginzler E, Sharon E, Diamond H, Kaplan D: Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975; 18:27-34.
36. Mertens HG, Hertel G, Reuther P, Ricker K: Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci 1981; 377:691-699.
37. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641-649.
38. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34:1081-1085.
39. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030.
40. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716-718.
41. Tavadia SM, Mydlarski PR, Reis MD, Mittmann N, Pinkerton PH, Shear N, et al: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42:628-632.
42. Corominas H, Domenech M, Gonzalez-Juan D, Gonzalez-Suarez B, Diaz C, Pujol J, et al: Aplasia medular tras administración de azatioprina: papel del polimorfismo genético de la tiopurina metiltransferasa. Med Clin (Barc) 2000; 115:299-301.
43. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
44. Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, et al: Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999; 38:944-947.
45. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K: Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87:108-111.
46. Leipold G, Schutz E, Haas JP, Oellerich M: Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997; 40:1896-1898.
47. Gummert JF, Schutz E, Oellerich M, Mohr FW, Dalichau H: Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine. Artif Organs 1995; 19:918-920.
48. Ben Ari Z, Mehta A, Lennard L, Burroughs AK: Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995; 23:351-354.
49. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA: Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:142-145.
50. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M: Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999; 38:640-644.
51. Sandborn WJ, Faubion WA: Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep 2000; 2:440-445.
52. Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, et al: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12:429-436.
53. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:1743-1750.
54. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, et al: Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory-bowel disease. Aliment Pharmacol Ther 2003; 18:395-400.
55. Sandborn WJ: Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48:591-592.
56. Corominas H, Domenech M, Gonzalez D, Diaz C, Roca M, Garcia-Gonzalez MA, et al: Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000; 95:2313-2317.
57. Regueiro M, Mardini H: Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002; 35:240-244.
58. Kader HA, Wenner WJ, Jr., Telega GW, Maller ES, Baldassano RN: Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30:409-413.